Exclusive partnership
SCHWIND eye-tech-solutions, Germany, has announced an exclusive partnership with ALPHAEON Corporation, US. SCHWIND has granted ALPHAEON the exclusive license to market SCHWIND AMARIS technology in the US. As part of the relationship, ALPHAEON will oversee and finance the US Food and Drug Administration (FDA) clinical trial required to market the product in the US. ALPHAEON, a wholly-owned subsidiary of Strathspey Crown Holdings LLC, closely cooperates with American eye surgeons to bring highly developed technologies to the US market. SCHWIND chief executive officer Rolf Schwind (pictured) said: “This cooperation is a historical milestone in the SCHWIND company history and for us, as a medium-sized family company, the best possible strategy to establish our cutting-edge technology in North America without entrepreneurial risks. We strongly believe that our partnership with ALPHAEON will build customer confidence and significantly impact the growth of patient procedures.”
www.eye-tech-solutions.com
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.